TIDMSAR
RNS Number : 2402S
Sareum Holdings PLC
02 November 2023
Sareum Holdings PLC
("Sareum" or the "Company")
Exercise of Share Options and Director Dealings
Cambridge, UK, 2 November 2023 - Sareum Holdings plc (AIM: SAR),
a biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer, announces that on 30
October 2023, Dr Tim Mitchell, Chief Executive Officer, and Dr John
Reader, Chief Scientific Officer, each exercised options over
95,040 ordinary shares of 1.25 pence each ("New Ordinary Shares")
in the Company (the "Options"), at an exercise price of 30 pence
per New Ordinary Share, for an aggregate consideration of
GBP57,024.
The Options were granted on 18 December 2013, under the Sareum
Holdings plc Enterprise Management Incentives Option Agreement, and
were due to lapse on 17 December 2023.
On exercise, Dr Mitchell and Dr Reader noted their intention to
sell a proportion of such New Ordinary Shares in the market on
receipt, partly in order to compensate for the cost and tax
liabilities arising from the exercise. A further announcement will
be released in due course disclosing such sales.
Following Admission (as defined below), Dr Mitchell's and Dr
Reader's resultant interests in the Company will be as follows:
Director/ Date of Number of Purchase Total shares Percentage
PDMR transaction shares purchased price held of issued
via Option share capital
exercise
T im Mitchell 30 October
(1) 2023 95,040 30p 1,104,561 1.57%
-------------- ------------------ --------- ------------- ---------------
J ohn Reader 30 October
(2) 2023 95,040 30p 1,127,537 1.60%
-------------- ------------------ --------- ------------- ---------------
(1) - Included within Tim Mitchell's total holding are 200,000
Ordinary Shares held by his spouse.
(2) - Included withing John Reader's total holding are 66,666
Ordinary Shares held by his spouse. Please note this record
corrects the typographical error in respect of John Reader's
shareholding announced on 3 November 2021.
Admission
Application has been made to the London Stock Exchange for the
190,080 New Ordinary Shares to be admitted to trading on AIM
("Admission") and it is expected that Admission will become
effective and trading will commence at 8.00 a.m. on 3 November
2023.
Following Admission, the total number of Ordinary Shares in
issue will be 70,261,878 and the total number of voting rights will
therefore be 70,261,878. This figure may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the share capital of the Company under the FCA's
Disclosure and Transparency Rules.
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497700
Lauren Williams, Head of Investor Relations ir@sareum.co.uk
Strand Hanson Limited (Nominated Adviser)
James Dance / James Bellman 020 7409 3494
Peel Hunt LLP (Joint Corporate Broker)
James Steel / Patrick Birkholm 020 7418 8900
Hybridan LLP (Joint Corporate Broker)
Claire Noyce
020 3764 2341
ICR Consilium (Financial PR)
Jessica Hodgson / Davide Salvi / Stella
Lempidaki 020 3709 5700
PDMR Notification Forms
The information set out below is provided in accordance with the
requirements of Article 19(3) of the EU Market Abuse Regulation No
596/2014.
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Tim Mitchell
-------------------------------- ----------------------------------------
2. Reason for the Notification
--------------------------------------------------------------------------
a) Position/status Chief Executive Officer
-------------------------------- ----------------------------------------
b) Initial notification/amendment Initial notification
-------------------------------- ----------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------
a) Name SAREUM HOLDINGS PLC
-------------------------------- ----------------------------------------
b) LEI 213800PKERN2DY8FFM72
-------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv)each place where transactions have
been conducted
--------------------------------------------------------------------------
a) Description of the Financial Ordinary shares of 1.25p each in the
instrument, type of instrument share capital of Sareum Holdings plc
-------------------------------- ----------------------------------------
Identification code ISIN for Ordinary Shares: GB00B02RFS12
-------------------------------- ----------------------------------------
b) Nature of the Transaction Exercise of Options to acquire ordinary
shares
-------------------------------- ----------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
30p 95,040 acquired
by way of an exercise
of options
-----------------------
-------------------------------- ----------------------------------------
d) Aggregated information Price(s) Volume(s)
* Aggregated volume 30p 95,040 acquired
by way of an exercise
of options
* Price -----------------------
-------------------------------- ----------------------------------------
e) Date of the transaction 30 October 2023
-------------------------------- ----------------------------------------
f) Place of the transaction London Stock Exchange (AIM)
-------------------------------- ----------------------------------------
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name John Reader
-------------------------------- ----------------------------------------
2. Reason for the Notification
--------------------------------------------------------------------------
a) Position/status Chief Scientific Officer
-------------------------------- ----------------------------------------
b) Initial notification/amendment Initial notification
-------------------------------- ----------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------
a) Name SAREUM HOLDINGS PLC
-------------------------------- ----------------------------------------
b) LEI 213800PKERN2DY8FFM72
-------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv)each place where transactions have
been conducted
--------------------------------------------------------------------------
a) Description of the Financial Ordinary shares of 0.025p each in
instrument, type of instrument the share capital of Sareum Holdings
plc
-------------------------------- ----------------------------------------
Identification code ISIN for Ordinary Shares: GB00B02RFS12
-------------------------------- ----------------------------------------
b) Nature of the Transaction Exercise of Options to acquire ordinary
shares
-------------------------------- ----------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
30p 95,040 acquired
by way of an exercise
of options
-----------------------
-------------------------------- ----------------------------------------
d) Aggregated information Price(s) Volume(s)
* Aggregated volume 30p 95,040 acquired
by way of an exercise
of options
* Price -----------------------
-------------------------------- ----------------------------------------
e) Date of the transaction 30 October 2023
-------------------------------- ----------------------------------------
f) Place of the transaction London Stock Exchange (AIM)
-------------------------------- ----------------------------------------
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology
company developing next generation kinase inhibitors for autoimmune
disease and cancer.
The Company is focused on developing next generation small
molecules which modify the activity of the JAK kinase family and
have best-in-class potential. Its lead candidate, SDC-1801,
simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential
treatment for a range of autoimmune diseases and has entered Phase
1a/b clinical development with an initial focus on psoriasis.
Sareum has an economic interest in SRA737, a clinical-stage Chk1
inhibitor which it originally developed in collaboration with
several Cancer Research UK-related organisations. SRA737 has shown
promising safety and efficacy in two Phase 1/2 clinical trials.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a
potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on
the AIM market of the London Stock Exchange, trading under the
ticker SAR. For further information, please visit the Company's
website at www.sareum.com
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDZMGMDZKGFZM
(END) Dow Jones Newswires
November 02, 2023 10:48 ET (14:48 GMT)
Sareum (LSE:SAR)
過去 株価チャート
から 4 2024 まで 5 2024
Sareum (LSE:SAR)
過去 株価チャート
から 5 2023 まで 5 2024